New Four-Pronged attack on advanced liver cancer begins testing
NCT ID NCT07150377
Summary
This study is testing a new combination of treatments for advanced liver cancer (hepatocellular carcinoma). It will give 41 participants a mix of two immunotherapy drugs (iparomlimab and tuvonralimab, together called QL1706), a targeted drug (lenvatinib), and a localized procedure (TACE). The main goal is to see how long the treatment can keep the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.